Menu
Search
|

Menu

Close
X

Second Sight Medical Products Inc EYES.OQ (NASDAQ Stock Exchange Capital Market)

0.84 USD
-- (--)
As of Mar 20
chart
Previous Close 0.84
Open --
Volume --
3m Avg Volume 74,184
Today’s High --
Today’s Low --
52 Week High 2.25
52 Week Low 0.64
Shares Outstanding (mil) 76.34
Market Capitalization (mil) 64.06
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
7
FY17
8
FY16
4
EPS (USD)
FY18
-0.533
FY17
-0.533
FY16
-0.859
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.82
Price to Sales (TTM)
vs sector
9.29
9.06
Price to Book (MRQ)
vs sector
19.13
4.61
Price to Cash Flow (TTM)
vs sector
--
40.52
Total Debt to Equity (MRQ)
vs sector
--
17.60
LT Debt to Equity (MRQ)
vs sector
--
13.95
Return on Investment (TTM)
vs sector
-640.05
12.09
Return on Equity (TTM)
vs sector
-640.05
13.20

EXECUTIVE LEADERSHIP

Gregg Williams
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Jonathan McGuire
President, Chief Executive Officer, Director, Since 2015
Salary: $394,000.00
Bonus: $86,680.00
John Blake
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Patrick Ryan
Chief Operating Officer, Since 2018
Salary: --
Bonus: --
Frank Vandeputte
Vice President, General Manager, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

12744 San Fernando Rd Bldg 3
SYLMAR   CA   91342-3853

Phone: +1818.8335000

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company intends to develop Orion Visual Cortical Prosthesis which provides useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease or forms of cancer and trauma. Its product, The Argus II Retinal Prosthesis System (The Argus II) provides electrical stimulation of the retina to induce visual perception in blind individuals and helps in treating outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.

SPONSORED STORIES